Data Safety Monitoring Board Recommends No Changes to SynerFuse™ Proof-of-Concept Study Protocol

SynerFuse, Inc., an Eden Prairie, Minnesota-based medical device company, announced today that an independent Data Safety and Monitoring Board (DSMB) met and recommended no changes after review of the first ten implanted subjects in the company’s ongoing proof-of-concept study.

The SynerFuse proof-of-concept study is a feasibility study being conducted under an Investigational Device Exemption (IDE) approved by the FDA. An independent DSMB composed of a neurosurgeon, an interventional pain medicine physician, and a biostatistician met on August 23 to review study data after ten subjects were followed through 10-20 days post-surgery. The DSMB determined that the study procedure met safety expectations and recommended to continue the study with no protocol modifications. The DSMB will continue to monitor subject safety data until the study is completed.

The SynerFuse proof-of-concept study involves combining spinal fusion with the implant of a neurostimulator to provide stimulation of the dorsal root ganglion (DRG), a key nerve structure along the spine that can be targeted with neuromodulation to address chronic neuropathic pain. The study is evaluating the safety and tolerability of the integrated therapy. Patients undergoing an initial spinal fusion, among other criteria, are eligible for the study.

“Gaining validation from the DSMB for the continued implementation of our proof-of-concept study is significant for SynerFuse, and we are thrilled about this milestone,” said SynerFuse co-founder, president, and CEO Justin Zenanko.

“Getting the green light from the DSMB once again to continue our proof-of-concept study with no changes to the protocol is a testament to the excellent collaboration we have experienced with our clinician partners,” said SynerFuse co-founder and Chief Scientific Officer Greg Molnar, Ph.D.



Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Kleiner Device Labs will attend the meeting and looks forward to demonstrating the new KG®2 Surge® flow-thru interbody system to surgeons
“Medtronic is continuing our efforts to stop Axonics from profiting off of their unauthorized use of our innovations and intellectual property," said Mira Sahney, president of the pelvic health business in the neuroscience portfolio at Medtronic. "The pattern is clear: Axonics uses Medtronic technologies to improperly compete in the market. It is time for Axonics to be held accountable for these unlawful acts."
The addition of Frank J Veith, MD to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies. His vast experience and achievements will provide critical insights and direction as ViTAA continues to pursue its goal of revolutionizing patient care through cutting-edge solutions.
Ultralife Corporation will join forces with cart manufacturer Karta to launch a complete medical cart and power solution on booth 1237 (Hall A) at HIMSS, from March 12-14, 2024 at the Orange County Convention Center in Orlando, Florida.
“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy